Research never stops


Dec 06, 2005

Evotec Reaches First Milestone and Receives Success Payment in Alzheimer's Disease Collaboration with Takeda

Nov 29, 2005

3i has reduced its interest in Evotec to 4.1%

Nov 14, 2005

Evotec Announces Initiation of Phase I Clinic Trial with EVT 101

Nov 09, 2005

Third Quarter 2005: Third consecutive quarter of strong services performance and first compound in Phase I clinical trials

Nov 03, 2005

Boehringer Ingelheim Extends Scope of Collaboration with Evotec into Screening Services - New agreements signed with Boehringer Ingelheim Germany and Canada

Oct 20, 2005

Evotec Reports Positive Results of Repositioning Clinical Trial on CNS Compound

Sep 08, 2005

ProPharma Integrated into Evotec Services Division

Aug 11, 2005

Second Quarter 2005: Evotec Progressing as Planned

Jul 25, 2005

Procter & Gamble Selects Evotec as Provider of Pharmaceutical Discovery and Chemical Development Services

Jul 21, 2005

Evotec Enters into Long-Term Focused Library Agreement with Almirall - Value Exceeding EUR 2.5 m over the Two-Year Contract Period

Jul 05, 2005

Evotec Names Dr Tim Tasker Executive Vice President Clinical Development and Member of the Executive Committee

Jun 24, 2005

Evotec Raised EUR 28.4 Million in Capital Increase

Jun 07, 2005

Evotec OAI Announces AGM Approval of Capital Increase and New Supervisory Board Structure

Jun 07, 2005

Evotec OAI Achieves First Milestone in Partnership with Boehringer Ingelheim

May 10, 2005

First Quarter 2005: Full-Year Guidance Confirmed Following Strong Q1 2005

May 06, 2005

Evotec OAI Proposes Changes to its Supervisory Board to Support the Implementation of its Strategy of Proprietary Drug Development

Apr 13, 2005

Evotec OAI Extends Global Medicinal Chemistry Agreement with Roche

Mar 22, 2005

Evotec OAI AG Report Financial Results 2004 and Guidance for 2005: Strong Q4 and Solid Outlook

Mar 06, 2005

Evotec Acquires ENS and Secures €47m in Cash to Develop CNS Pipeline

Feb 16, 2005

Evotec OAI to Provide Process Validation for AnorMED Inc. Phase III Compound, AMD 3100

Feb 03, 2005

Evotec OAI's Preliminary Results 2004: Strong Q4 Performance

Jan 19, 2005

Evotec OAI Appoints Mary Tanner to its Supervisory Board: New Board Member brings significant life science and investment banking expertise